DE602004025509D1 - Virales latentphasen-interleukin-10-(vii-10) und verwendungen davon - Google Patents

Virales latentphasen-interleukin-10-(vii-10) und verwendungen davon

Info

Publication number
DE602004025509D1
DE602004025509D1 DE602004025509T DE602004025509T DE602004025509D1 DE 602004025509 D1 DE602004025509 D1 DE 602004025509D1 DE 602004025509 T DE602004025509 T DE 602004025509T DE 602004025509 T DE602004025509 T DE 602004025509T DE 602004025509 D1 DE602004025509 D1 DE 602004025509D1
Authority
DE
Germany
Prior art keywords
virus
interleukin
latent phase
vii
homologue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004025509T
Other languages
English (en)
Inventor
Barry Slobedman
Allison Denise Abendroth
Christina Anne Jenkins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Sydney
Original Assignee
University of Sydney
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2003906613A external-priority patent/AU2003906613A0/en
Application filed by University of Sydney filed Critical University of Sydney
Publication of DE602004025509D1 publication Critical patent/DE602004025509D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Transplantation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DE602004025509T 2003-11-28 2004-11-26 Virales latentphasen-interleukin-10-(vii-10) und verwendungen davon Active DE602004025509D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2003906613A AU2003906613A0 (en) 2003-11-28 Interleukin-10 Homologue and Uses Thereof
PCT/AU2004/001675 WO2005052159A1 (en) 2003-11-28 2004-11-26 Latent phase viral interleukin-10-(vii-10) and uses thereof

Publications (1)

Publication Number Publication Date
DE602004025509D1 true DE602004025509D1 (de) 2010-03-25

Family

ID=34624267

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004025509T Active DE602004025509D1 (de) 2003-11-28 2004-11-26 Virales latentphasen-interleukin-10-(vii-10) und verwendungen davon

Country Status (6)

Country Link
US (2) US8133700B2 (de)
EP (1) EP1702068B1 (de)
AT (1) ATE457353T1 (de)
AU (1) AU2004293499B2 (de)
DE (1) DE602004025509D1 (de)
WO (1) WO2005052159A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2367891T3 (es) 2000-09-29 2011-11-10 Schering Corporation Interleucina-10 pegilada.
DK2379115T3 (da) 2008-12-17 2018-01-29 Merck Sharp & Dohme Fremstilling og anvendelse af mono- og di-PEG-IL-10
CA2908198A1 (en) 2013-04-18 2014-10-23 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
JP2016528879A (ja) 2013-06-17 2016-09-23 アルモ・バイオサイエンシーズ・インコーポレイテッド タンパク質の同一性および安定性を評価する方法
US10010588B2 (en) 2013-08-30 2018-07-03 Armo Biosciences, Inc. Methods of using pegylated interleukin-10 for treating hyperlipidemia
US20160243216A1 (en) * 2013-10-29 2016-08-25 The University Of Sydney Cmv immuno-stimulatory composition
WO2015070060A1 (en) 2013-11-11 2015-05-14 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US10293043B2 (en) 2014-06-02 2019-05-21 Armo Biosciences, Inc. Methods of lowering serum cholesterol
JP2017536098A (ja) 2014-10-14 2017-12-07 アルモ・バイオサイエンシーズ・インコーポレイテッド インターロイキン−１５組成物及びその使用
US10143726B2 (en) 2014-10-22 2018-12-04 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2016126615A1 (en) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2016168741A2 (en) * 2015-04-16 2016-10-20 Spencer Juliet V Detection of human cytomegalovirus
US20160361415A1 (en) 2015-05-28 2016-12-15 Armo Biosciences, Inc. Methods of Using Interleukin-10 for Treating Diseases and Disorders
AU2016312510A1 (en) 2015-08-25 2018-03-08 Armo Biosciences, Inc. Methods of using Interleukin-10 for treating diseases and disorders
CN114349858B (zh) * 2022-01-26 2022-07-01 优睿赛思(武汉)生物科技有限公司 抗人白介素-10高亲和力兔单克隆抗体及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001016153A1 (en) 1999-09-02 2001-03-08 University Of Medicine And Dentistry Of New Jersey Cytomegalovirus-encoded il-10 homolog
US6692954B1 (en) 2000-11-03 2004-02-17 The Scripps Research Institute Generation of human cytomegalovirus yeast artificial chromosome recombinants
EP1379637A4 (de) 2001-03-27 2005-04-06 Dendreon Corp Transmembran-serinprotease 9 codierende nukleinsäuremoleküle, die codierten polypeptide sowie darauf beruhende verfahren
US7361460B2 (en) * 2003-04-11 2008-04-22 Digene Corporation Approach to molecular diagnosis of human papillomavirus-related diseases
WO2005012545A2 (en) * 2003-07-25 2005-02-10 The Regents Of The University Of California Cytomegalovirus gene function and methods for developing antivirals, anti-cmv vaccines, and cmv-based vectors

Also Published As

Publication number Publication date
WO2005052159A8 (en) 2005-08-18
WO2005052159A1 (en) 2005-06-09
US8133700B2 (en) 2012-03-13
AU2004293499B2 (en) 2009-11-26
ATE457353T1 (de) 2010-02-15
AU2004293499A1 (en) 2005-06-09
US20090214463A1 (en) 2009-08-27
EP1702068A1 (de) 2006-09-20
US20120134957A1 (en) 2012-05-31
EP1702068B1 (de) 2010-02-10
EP1702068A4 (de) 2007-07-11

Similar Documents

Publication Publication Date Title
DE602004025509D1 (de) Virales latentphasen-interleukin-10-(vii-10) und verwendungen davon
ATE364698T1 (de) Neues, physiologisch aktives peptid und dessen verwendung
CL2003001743A1 (es) Compuestos derivados de leucinamida, inhibidores de la cisteina proteasa; composicion farmaceutica; procedimiento de preparacion de la composicion farmaceutica; y su uso en el tratamiento de la osteoporosis, enfermedad de paget's, peridontal, perdida
EA200400023A1 (ru) Ингибиторы вич-протеазы, содержащие их композиции, их фармацевтическое использование и материалы для их синтеза
DE602004022061D1 (de) Verwendung von modifizierten cyclosporinen zur behandlung von hcv-erkrankungen
BR0012919A (pt) Vacina para uso na profilaxia e/ou no tratamento da sìndrome de ponto branco (white spot syndrome) em crustáceos, proteìna estrutural derivada do vìrus da sìndrome de ponto branco, sequência de ácido nucléico, uso de uma proteìna estrutural, composição farmacêutica, anticorpos, vacina ou formulação farmacêutica, e, kit diagnóstico para detecção de wssv
NO20052956D0 (no) Defensinprotiner
ATE256667T1 (de) Verbindungen und deren verwendung zur behandlung von infektiösen erkrankungen
DK1007685T3 (da) Overfladeeksponerede proteiner fra chlamydia pneumoniae
WO2007030708A3 (en) Antimicrobial adzymes and uses thereof
EA200501711A1 (ru) Семейство секретируемых белков
WO2005051318A3 (en) Compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases
ATE549352T1 (de) Verwendung sekretierter proteinprodukte zur prävention und behandlung von erkrankungen der bauchspeicheldrüse und/oder adipositas und/oder des metabolischen syndroms
ATE397624T1 (de) Cystine-knot fold protein
NO20054900L (no) Sekrert proteinfamilie
ATE328080T1 (de) Proteine und für diese kodierende dna
PT816504E (pt) Acetil-hidrolase para o factor activador das plaquetas, e seu gene
ATE411812T1 (de) Peptide zur behandlung von infektionen mit dem herpes-virus
WO2004014936A3 (fr) Melange de peptides issus des proteines c et ns3 du virus de l'hepatite c et leurs applications.
IL169256A (en) Polypeptide having metalloprotease activity, nucleic acid encoding it and pharmaceutical composition comprising it
NO20016344D0 (no) Nye polypeptider og deres DNA
HUP0302416A2 (hu) Tisztított hepatitis-C vírusmembrán-proteinek diagnosztikai és terápiás célú alkalmazása
DE69824001D1 (de) Reagenz zum nachweis und weiterverfolgen von virusinfektionen
DE60124523D1 (de) Zusammensetzung einer Parvovirus VP1-Proteinvariante und eines arvovirus NS1-Proteins zur Induktion von Zytolyse
De Recent Discovery of Peptidomimetics for the Treatment of Coronavirus (COVID-19), Human Coronavirus, and Enteroviruses

Legal Events

Date Code Title Description
8364 No opposition during term of opposition